Introduction of the NeuroEnhancement PlatformTM

The NeuroEnhancement PlatformTM (NEP) is a neurodiagnostic and neuromodulation platform that allows the simultaneous assessment of cognitive, behavioral and motor functioning with electrical neuroimaging.   

The uniqueness of the NEP system is that it enhances the relevance between neuroimaging findings and the cortical functional test results.   This system consolidates multiple separate processes:  cortical functional assessment, neuroimaging, target optimization, neuromodulation and re-testing which takes a minimum of approximately one month in a typical clinical or research setting to coordinate all the diagnostics in order to implement a treatment protocol and consolidates this process down to an hour of diagnostics and treatment implementation.  

This markedly reduces the chance for misinterpretation i.e., assuming deviations on neuroimaging measured outside of the functional assessment is relative to a patient’s or subjects deficits or weaknesses.  Because the functional based deficit(s) is linked in real-time to the neurophysiological deviation during the testing the risk for misinterpretation is reduced and the accuracy of the NM treatment protocol enhanced.    

Neurodiagnostics capabilities of the NEP

  • Artifact identification and cancelation
  • Target Optimization
  • Source Localization
  • Functional Connectivity
  • ERPs Package
  • Seizure Detection
  • Co-registration platform for HD-EEG, fMRI and sMRI
  • Neurodegenerative Disease Neuromarker Analysis
  • ADHD Neuromarker Analysis
  • Concussion Neuromarker Analysis
  • Anxiety Neuromarker

Non-invasive Neuromodulation (NM)

Introduction

Non-invasive neuromodulation (NM) has a long history over the past century and encompasses many forms of research and clinical applications applying electrical currents to the brain.  NM does not require any surgery or anesthesia and generally uses low intensity currents – typically in the range of 1-2 mA with one or more electrodes on the head. The general targets have traditionally been the cortex and the trigeminal nerve, and more recently, the auricular branch of the vagus nerve.  NM has been shown to modulate cortical excitability and continues to be extensively studied in healthy and various clinical populations.  NM comprises a number of different techniques, including transcranial direct current stimulation (tDCS), alternating current stimulation (tACS) and random noise stimulation (tRNS). The current delivered in NM techniques is not powerful enough to elicit an action potential and is maintained at subthreshold levels to effect cortical excitability only (Radman et al. 2009; Reed and Kadosh, 2018). The treatment efficacy of various forms of NM continues to expand and has received approval in the treatment of epilepsy, major depression, anxiety disorders, insomnia, migraine, chronic pain and more recently attention deficit and hyperactivity disorder (ADHD).  For instance, transcranial direct current stimulation (tDCS) has been approved in several non-US countries for the treatment of depression and pain.  Another form of NM is cranial electrotherapy stimulation (CES) which received approval in the US in the late 1970s for the treatment of anxiety/insomnia and depression.